Viral vectors for in vivo gene transfer in Parkinson's disease: Properties and clinical grade production

Experimental Neurology

Volumn 209, Issue 1, 2008, Pages 58-71

  Mandel, Ronald J ^a,b,c   Burger, Corinna ^d   Snyder, Richard O ^a,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Adeno associated virus; Adenovirus; Cleanroom; Herpes simplex virus; Lentivirus; Purification; Quality assurance; Quality control

Indexed keywords

ADENOVIRUS VECTOR; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; PLASMID DNA; REAGENT; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ARTICLE; CELL CULTURE; DNA HYBRIDIZATION; GENE EXPRESSION; GOOD MANUFACTURING PRACTICE; HERPES SIMPLEX VIRUS; IN VIVO GENE TRANSFER; LENTIVIRINAE; METHODOLOGY; NONHUMAN; OSMOLARITY; PARKINSON DISEASE; PH; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN PURIFICATION; PURIFICATION; QUALITY CONTROL; SAFETY; STANDARD; TECHNOLOGY; TRAINING; TRANSGENE; VIRUS RECOMBINANT;

ANIMALS; DRUG INDUSTRY; GENE THERAPY; GENETIC VECTORS; HUMANS; PARKINSON DISEASE; PLASMIDS; VIRUSES;

EID: 37549054118     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.08.008     Document Type: Article

References (113)

1. Akli S., Caillaud C., Vigne E., Stratford-Perricaudet L.D., Poenaru L., Perricaudet M., Kahn A., and Peschanski M.R. Transfer of a foreign gene into the brain using adenovirus vectors. Nat. Genet. 3 (1993) 224-228
2. Azzouz M., Martin-Rendon E., Barber R.D., Mitrophanous K.A., Carter E.E., Rohll J.B., Kingsman S.M., Kingsman A.J., and Mazarakis N.D. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J. Neurosci. 22 (2002) 10302-10312
3. Barkats M., Bilang-Bleuel A., Buc-Caron M.H., Castel-Barthe M.N., Corti O., Finiels F., Horellou P., Revah F., Sabate O., and Mallet J. Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases. Prog. Neurobiol. 55 (1998) 333-341
4. Bergelson J.M., Cunningham J.A., Droguett G., Kurt-Jones E.A., Krithivas A., Hong J.S., Horwitz M.S., Crowell R.L., and Finberg R.W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275 (1997) 1320-1323
5. Bilang-Bleuel A., Revah F., Colin P., Locquet I., Robert J.J., Mallet J., and Horellou P. Intrastriatal injection of an adenoviral vector expression glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 8818-8823
6. Blömer U., Naldini L., Kafri T., Trono D., Verma I.M., and Gage F.H. Highly efficient and sustained gene transfer in adult neurons and lentivirus vector. J. Virol. 71 (1997) 6641-6649
7. Bohn M.C., Choi-Lundberg D.L., Davidson B.L., Leranth C., Kozlowski D.A., Smith J.C., O'Banion M.K., and Redmond D. Adenovirus-mediated transgene expression in nonhuman primate brain. Hum. Gene Ther. 10 (1999) 1175-1184
8. Booth M.J., Mistry A., Li X., Thrasher A., and Coffin R.S. Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids. Gene Ther. 11 (2004) 829-837
9. Burger C., Gorbatyuk O., Velardo M.J., Peden C.S., Williams P., Zolotukhin S., Reier P.J., Mandel R.J., and Muzyczka N. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Molec. Ther. 10 (2004) 302-317
10. Burger C., Nash K., and Mandel R.J. Recombinant adeno-associated viral vectors in the nervous system. Hum. Gene Ther. 16 (2005) 781-791
11. Burton E.A., Fink D.J., and Glorioso J.C. Gene delivery using herpes simplex virus vectors. DNA Cell Biol. 21 (2002) 915-936
12. Burton E.A., Glorioso J.C., and Fink D.J. Gene therapy progress and prospects: Parkinson's disease. Gene Ther. 10 (2003) 1721-1727
13. Burton E.A., Fink D.J., and Glorioso J.C. Replication-defective genomic HSV gene therapy vectors: design, production and CNS applications. Curr. Opin. Mol. Ther. 7 (2005) 326-336
14. Byrnes A.P., Rusby J.E., Wood M.J.A., and Charlton H.M. Adenovirus gene transfer causes inflammation in the brain. Neuroscience 66 (1995) 1015-1024
15. Byrnes A.P., Wood M.J., and Charlton H.M. Role of T cells in inflammation caused by adenovirus vectors in the brain. Gene Ther. 3 (1996) 644-651
16. Candolfi M., Curtin J.F., Xiong W.D., Kroeger K.M., Liu C., Rentsendorj A., Agadjanian H., Medina-Kauwe L., Palmer D., Ng P., Lowenstein P.R., and Castro M.G. Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Molec. Ther. 14 (2006) 371-381
17. Cao L., Liu Y., During M.J., and Xiao W. High-titer, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids. J. Virol. 74 (2000) 11456-11463
18. Carr D.J., and Tomanek L. Herpes simplex virus and the chemokines that mediate the inflammation. Curr. Top. Microbiol. Immunol. 303 (2006) 47-65
19. Choi-Lundberg D.L., Lin Q., Chang L.N., Chiang L., Hay C.M., Mohajeri H., Davidson B.L., and Bohn M.C. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275 (1997) 838-841
20. Clark K.R., Liu X., McGrath J.P., and Johnson P.R. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum. Gene Ther. 10 (1999) 1031-1039
21. Conway J.E., Zolotukhin S., Muzyczka N., Hayward G.S., and Byrne B.J. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J. Virol. 71 (1997) 8780-8789
22. Corti O., Sabaté O., Horellou P., Colin P., Dumas S., Buchet D., Buc-Caron M.H., and Mallet J. A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors. Nat. Biotechnol. 17 (1999) 349-354
23. Danthinne X., and Imperiale M.J. Production of first generation adenovirus vectors: a review. Gene Ther. 7 (2000) 1707-1714
24. Dass B., Olanow C.W., and Kordower J.H. Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. Neurology 66 (2006) S89-S103
25. Davidson B.L., Stein C.S., Heth J.A., Martins I., Kotin R.M., Derksen T.A., Zabner J., Ghodsi A., and Chiorini J.A. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3428-3432
26. Dewey R.A., Morrissey G., Cowsill C.M., Stone D., Bolognani F., Dodd N.J., Southgate T.D., Klatzmann D., Lassmann H., Castro M.G., and Lowenstein P.R. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat. Med. 5 (1999) 1256-1263
27. Do Thi N.A., Saillour P., Ferrero L., Dedieu J.F., Mallet J., and Paunio T. Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease. Gene Ther. 11 (2004) 746-756
28. Donsante A., Miller D.G., Li Y., Vogler C., Brunt E.M., Russell D.W., and Sands M.S. AAV vector integration sites in mouse hepatocellular carcinoma. Science 317 (2007) 477
29. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., and Naldini L. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72 (1998) 8463-8471
30. Escarpe P., Zayek N., Chin P., Borellini F., Zufferey R., Veres G., and Kiermer V. Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV-based vector preparations. Molec. Ther. 8 (2003) 332-341
31. Farson D., Harding T.C., Tao L., Liu J., Powell S., Vimal V., Yendluri S., Koprivnikar K., Ho K., Twitty C., Husak P., Lin A., Snyder R.O., and Donahue B.A. Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors. J. Gene Med. 6 (2004) 1369-1381
32. FDA. Points to Consider in Production and Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology (1985), Office of Biologics Research and Review Center for Drugs and Biologics
33. Fink D.J., and Glorioso J.C. Engineering herpes simplex virus vectors for gene transfer to neurons. Nat. Med. 3 (1997) 357-359
34. Fink D.J., Poliani P.L., Oligino T., Krisky D.M., Goins W.F., and Glorioso J.C. Development of an HSV-based vector for the treatment of Parkinson's disease. Exp. Neurol. 144 (1997) 103-121
35. Fraefel C., Jacoby D.R., and Breakefield X.O. Herpes simplex virus type 1-based amplicon vector systems. Adv. Virus Res. 55 (2000) 425-451
36. Gao G.P., Alvira M.R., Wang L., Calcedo R., Johnston J., and Wilson J.M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11854-11859
37. Gao G., Vandenberghe L.H., Alvira M.R., Lu Y., Calcedo R., Zhou X., and Wilson J.M. Clades of Adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78 (2004) 6381-6388
38. Gao G., Vandenberghe L.H., and Wilson J.M. New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5 (2005) 285-297
39. Gerdes C.A., Castro M.G., and Lowenstein P.R. Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo. Molec. Ther. 2 (2000) 330-338
40. Hardy S., Kitamura M., Harris-Stansil T., Dai Y., and Phipps M.L. Construction of adenovirus vectors through Cre-lox recombination. J. Virol. 71 (1997) 1842-1849
41. Harui A., Suzuki S., Kochanek S., and Mitani K. Frequency and stability of chromosomal integration of adenovirus vectors. J. Virol. 73 (1999) 6141-6146
42. Hauswirth W.W., Lewin A.S., Zolotukhin S., and Muzyczka N. Production and purification of recombinant adeno-associated virus. Methods Enzymol. 316 (2000) 743-761
43. Hillgenberg M., Tonnies H., and Strauss M. Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer. J. Virol. 75 (2001) 9896-9908
44. Huszthy P.C., Svendsen A., Wilson J.M., Kotin R.M., Lonning P.E., Bjerkvig R., and Hoover F. Widespread dispersion of adeno-associated virus serotype 1 and adeno-associated virus serotype 6 vectors in the rat central nervous system and in human glioblastoma multiforme xenografts. Hum. Gene Ther. 16 (2005) 381-392
45. Kamen A., and Henry O. Development and optimization of an adenovirus production process. J. Gene Med. 6 Suppl 1 (2004) S184-S192
46. Kay, M.A., Nakai, H., Nakai, H., Montini, E., Fuess, S., Storm, T.A., Grompe, M., Kay, M.A., 2003. Looking into the safety of AAV vectors: AAV serotype 2 vectors preferentially integrate into active genes in mice. Nature: Nat Genet 424. 34, 251, 297-302.
47. Kim V.N., Mitrophanous K., Kingsman S.M., and Kingsman A.J. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J. Virol. 72 (1998) 811-816
48. Klein J.A., and Ackerman S.L. Oxidative stress, cell cycle, and neurodegeneration. J. Clin. Invest. 111 (2003) 785-793
49. Klein R.L., Meyer E.M., Peel A.L., Zolotukhin S., Meyers C., Muzyczka N., and King M.A. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp. Neurol. 150 (1998) 183-194
50. Kohlbrenner E., Aslanidi G., Nash K., Shklyaev S., Campbell-Thompson M., Byrne B.J., Snyder R.O., Muzyczka N., Warrington Jr. K.H., and Zolotukhin S. Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Molec. Ther. 12 (2005) 1217-1225
51. Kordower J.H., and Olanow W.C. Regulatable promoters and gene therapy for parkinson's disease: is the only thing to fear, fear itself?. Exp. Neurol. 209 (2008) 34-40
52. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., and Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
53. Kotin R.M., Siniscalco M., Samulski R.J., Zhu X.D., Hunter L., Laughlin C.A., McLaughlin S., Muzyczka N., Rocchi M., and Berns K.I. Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 2211-2215
54. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
55. Le Gal La Salle G., Robert J.J., Berrard S., Ridoux V., Stratford-Perricaudet L.D., Perricaudet M., and Mallet J. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 259 (1993) 988-990
56. Lowenstein P.R. Input virion proteins: cryptic targets of antivector immune responses in preimmunized subjects. Molec. Ther. 9 (2004) 771-774
57. Lowenstein P.R., and Castro M.G. Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences. Gene Ther. 10 (2003) 946-954
58. Lowenstein P.R., Thomas C.E., Umana P., Gerdes C.A., Verakis T., Boyer O., Tondeur S., Klatzmann D., and Castro M.G. High-capacity, helper-dependent, "gutless" adenoviral vectors for gene transfer into brain. Methods Enzymol. 346 (2002) 292-311
59. Lowenstein, P.R., Mandel, R.J., Xiong, W.-d., Kroeger, K.M., Castro, M.G., in press. Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr. Gene Ther.
60. Mandel R.J., and Burger C. Clinical trials in neurological disorders using AAV vectors: promises and challenges. Curr. Opin. Mol. Ther. 6 (2004) 482-490
61. Mandel R.J., Manfredsson F.P., Foust K.D., Rising A., Reimsnider S., Nash K., and Burger C. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Molec. Ther. 13 (2006) 463-483
62. Millhouse S., and Wigdahl B. Molecular circuitry regulating herpes simplex virus type 1 latency in neurons. J. Neurovirology 6 (2000) 6-24
63. Mitchell R.S., Beitzel B.F., Schroder A.R., Shinn P., Chen H., Berry C.C., Ecker J.R., and Bushman F.D. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2 (2004) E234
64. Mitta B., Rimann M., and Fussenegger M. Detailed design and comparative analysis of protocols for optimized production of high-performance HIV-1-derived lentiviral particles. Metab. Eng. 7 (2005) 426-436
65. Mittereder N., March K.L., and Trapnell B.C. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70 (1996) 7498-7509
66. Miyoshi H., Blomer U., Takahashi M., Gage F.H., and Verma I.M. Development of a self-inactivating lentivirus vector. J. Virol. 72 (1998) 8150-8157
67. Moralli D., Simpson K.M., Wade-Martins R., and Monaco Z.L. A novel human artificial chromosome gene expression system using herpes simplex virus type 1 vectors. EMBO Rep. 7 (2006) 911-918
68. Murakami P., Pungor E., Files J., Do L., van Rijnsoever R., Vogels R., Bout A., and McCaman M. A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles. Hum. Gene Ther. 13 (2002) 909-920
69. Muruve D.A. The innate immune response to adenovirus vectors. Hum. Gene Ther. 15 (2004) 1157-1166
70. Muzyczka N., and Berns K.I. Parvoiridae; the viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology (2001), Lippincott, Williams and Wilkins, New York 2327-2360
71. Naldini L., and Verma I.M. Lentiviral vectors. Adv. Virus Res. 55 (2000) 599-609
72. Naldini L., Blömer U., Gage F.H., Trono D., and Verma I.M. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 11382-11388
73. Naldini L., Blömer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., and Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267
74. Nienhuis A.W. Assays to evaluate the genotoxicity of retroviral vectors. Molec. Ther. 14 (2006) 459-460
75. Nony P., Chadeuf G., Tessier J., Moullier P., and Salvetti A. Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) type 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles. J. Virol. 77 (2003) 776-781
76. Oehmig A., Fraefel C., and Breakefield X.O. Update on herpesvirus amplicon vectors. Molec. Ther. 10 (2004) 630-643
77. Oehmig A., Fraefel C., Breakefield X.O., and Ackermann M. Herpes simplex virus type 1 amplicons and their hybrid virus partners, EBV, AAV, and retrovirus. Curr. Gene Ther. 4 (2004) 385-408
78. Olanow C.W., and Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22 (1999) 123-144
79. Palfi S., Leventhal L., Chu Y., Ma S.Y., Emborg M., Bakay R., Deglon N., Hantraye P., Aebischer P., and Kordower J.H. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J. Neurosci. 22 (2002) 4942-4954
80. Parks R.J., Chen L., Anton M., Sankar U., Rudnicki M.A., and Graham F.L. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 13565-13570
81. Peden C.S., Burger C., Muzyczka N., and Mandel R.J. Circulating anti-wt-AAV2 antibodies inhibit rAAV2-, but not rAAV5-mediated gene transfer in the brain. J. Virol. 78 (2004) 6344-6359
82. Puntel M., Curtin J.F., Zirger J.M., Muhammad A.K., Xiong W., Liu C., Hu J., Kroeger K.M., Czer P., Sciascia S., Mondkar S., Lowenstein P.R., and Castro M.G. Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. Hum. Gene Ther. 17 (2006) 531-544
83. Qing K., Mah C., Hansen J., Zhou S., Dwarki V., and Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5 (1999) 71-77
84. Reimsnider S., Manfredsson F.P., Muzyczka N., and Mandel R.J. Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Molec. Ther. (2007)
85. Roizman B., and Sears A.E. An inquiry into the mechanisms of herpes simplex virus latency. Annu. Rev. Microbiol. 41 (1987) 543-571
86. Sanftner L.M., Suzuki B.M., Doroudchi M.M., Feng L., McClelland A., Forsayeth J.R., and Cunningham J. Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. Molec. Ther. 9 (2004) 403-409
87. Sastry L., Johnson T., Hobson M.J., Smucker B., and Cornetta K. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther. 9 (2002) 1155-1162
88. Sastry L., Xu Y., Duffy L., Koop S., Jasti A., Roehl H., Jolly D., and Cornetta K. Product-enhanced reverse transcriptase assay for replication-competent retrovirus and lentivirus detection. Hum. Gene Ther. 16 (2005) 1227-1236
89. Segura, M.M., Garnier, A., Durocher, Y., Coelho, H., Kamen, A., in press. Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification Biotechnol. Bioeng. (Electronic publication ahead of print).
90. Shah A.C., Benos D., Gillespie G.Y., and Markert J.M. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J. Neuro-Oncol. 65 (2003) 203-226
91. Shenk T. Adenoviridae: the viruses and their replication. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fundamental Virology (1996), Lippincott-Raven Co., New York 979-1016
92. Sinn P.L., Sauter S.L., and McCray Jr. P.B. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther. 12 (2005) 1089-1098
93. Snyder R.O., and Francis J. Adeno-associated viral vectors for clinical gene transfer studies. Curr. Gene Ther. 5 (2005) 311-321
94. Sommer J.M., Smith P.H., Parthasarathy S., Isaacs J., Vijay S., Kieran J., Powell S.K., McClelland A., and Wright J.F. Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Molec. Ther. 7 (2003) 122-128
95. Sondhi D., Hackett N.R., Peterson D.A., Stratton J., Baad M., Travis K.M., Wilson J.M., and Crystal R.G. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Molec. Ther. 15 (2007) 481-491
96. Soubrier F., Laborderie B., and Cameron B. Improvement of pCOR plasmid copy number for pharmaceutical applications. Appl. Microbiol. Biotechnol. 66 (2005) 683-688
97. Summerford C., and Samulski R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72 (1998) 1438-1445
98. Summerford C., Bartlett J.S., and Samulski R.J. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5 (1999) 78-82
99. Taymans J.M., Vandenberghe L.H., Haute C.V., Thiry I., Deroose C.M., Mortelmans L., Wilson J.M., Debyser Z., and Baekelandt V. Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum. Gene Ther. (2007)
100. Thomas C.E., Birkett D., Anozie I., Castro M.G., and Lowenstein P.R. Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Molec. Ther. 3 (2001) 36-46
101. Thomas C.E., Schiedner G., Kochanek S., Castro M.G., and Lowenstein P.R. Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum. Gene Ther. 12 (2001) 839-846
102. Tollefson A.E., Kuppuswamy M., Shashkova E.V., Doronin K., and Wold W.S. Preparation and titration of CsCl-banded adenovirus stocks. Methods Mol. Med. 130 (2007) 223-235
103. Tyler C.M., Wuertzer C.A., Bowers W.J., and Federoff H.J. HSV amplicons: neuro applications. Curr. Gene Ther. 6 (2006) 337-350
104. Verma I.M., and Weitzman M.D. Gene therapy: twenty-first century medicine. Ann. Rev. Biochem. 74 (2005) 711-738
105. Wang Z., Zhu T., Qiao C., Zhou L., Wang B., Zhang J., Chen C., Li J., and Xiao X. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23 (2005) 321-328
106. Wood M.J., Charlton H.M., Wood K.J., Kajiwara K., and Byrnes A.P. Immune responses to adenovirus vectors in the nervous system. Trends Neurosci. 19 (1996) 497-501
107. Yant S.R., Ehrhardt A., Mikkelsen J.G., Meuse L., Pham T., and Kay M.A. Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat. Biotechnol. 20 (2002) 999-1005
108. Zaiss A.K., and Muruve D.A. Immune responses to adeno-associated virus vectors. Curr. Gene Ther. 5 (2005) 323-331
109. Zermansky A.J., Bolognani F., Stone D., Cowsill C.M., Morrissey G., Castro M.G., and Lowenstein P.R. Towards global and long-term neurological gene therapy: unexpected transgene dependent, high-level, and widespread distribution of HSV-1 thymidine kinase throughout the CNS. Molec. Ther. 4 (2001) 490-498
110. Zhu Z.H., Chen S.S., and Huang A.S. Phenotypic mixing between human immunodeficiency virus and vesicular stomatitis virus or herpes simplex virus. J. Acquir. Immune Defic. Syndr. 3 (1990) 215-219
111. Zolotukhin S., Potter M., Zolotukhin I., Sakai Y., Loiler S., Fraites T.J.J., Chiodo V.A., Phillipsberg T., Muzyczka N., Hauswirth W.W., Flotte T.R., Byrne B.J., and Snyder R.O. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002) 158-167
112. Zufferey R., Nagy D., Mandel R.J., Naldini L., and Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15 (1997) 871-875
113. Zufferey R., Dull T., Mandel R.J., Bukovsky A., Quiroz D., Naldini L., and Trono D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72 (1998) 9873-9880